Publications by authors named "Julia Riffel"

5 Publications

  • Page 1 of 1

Low risk of contrast media induced hypersensitivity reactions in all subtypes of systemic mastocytosis.

Ann Allergy Asthma Immunol 2021 Oct 9. Epub 2021 Oct 9.

Clinic of Clinical Radiology and Nuclear Medicine, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. Electronic address:

Background: Patients with SM are at increased risk of hypersensitivity reactions. Although hymenoptera venoms are the predominant triggers, cases of CMIHR have also been reported and prophylactic premedication is often performed. However, data from larger series are limited and differences between indolent and advanced systemic mastocytosis have not yet been investigated.

Objective: To determine the incidence and severity of CMIHR in all subtypes of SM.

Methods: We analyzed 162 adult patients with SM (ISM, n=65; advSM, n=97). Firstly, the cumulative incidence of CMIHR was retrospectively assessed in the patient's history. Secondly, at our institution, patients underwent 332 CM-enhanced imagings including 80 CT scans with iodine-based contrast agent and 252 MRI with gadoliniumbased contrast agent and tolerance was assessed.

Results: Previous CMIHRs to CT (vomiting, n=1, erythema, n=1, cardiovascular shock, n=1) and MRI (dyspnea, n=1, cardiovascular shock, n=1) had been reported by 4/162 (2.5%) patients (ISM, n=3; advSM, n=1). In contrast, during or after 332 CM-enhanced CT/MRI examinations at our institution, no CMIHRs were reported. Premedication was solely given to 3 patients prior to CT scans, including one with previous CMIHR, who tolerated the imaging well.

Conclusion: We conclude that i) there is a significant discrepancy between perception and prevalence of hypersensitivity reactions to CM in SM, ii) reactions are scarce in ISM and even rarer in advSM, iii) in SM patients without previous history of CM hypersensitivity, prophylactic premedication prior to CM enhanced-CT/MRI is dispensable.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2021.10.004DOI Listing
October 2021

T2-weighted Imaging of the Breast at 1.5T Using Simultaneous Multi-slice Acceleration.

Anticancer Res 2021 Sep;41(9):4423-4429

Clinic of Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Aim: To evaluate the image quality and time saving using simultaneous multi-slice (SMS)-accelerated T2-weighted turbo spin echo (TSE) sequences compared to standard T2 TSE sequences in breast magnetic resonance imaging (MRI).

Patients And Methods: Thirty patients were examined with an SMS-accelerated T2 TSE sequence and a standard T2 TSE sequence as part of a breast MRI protocol at 1.5T. Image quality, signal homogeneity and tissue delineation were evaluated. For quantitative assessment, the signal-to-noise ratio (SNR) was measured from representative SNR maps.

Results: There were no significant differences regarding tissue delineation and signal homogeneity. Image quality was rated equal at the chest wall and the breasts but decreased in the axilla on SMS-T2 TSE (p=0.01) with a simultaneous decrease of SNR (p=0.03). This did not significantly impact the overall image quality (p=0.2). The acquisition time for SMS-T2 TSE was 48% shorter compared to standard T2 TSE.

Conclusion: SMS-acceleration for T2-weighted imaging of the breast at 1.5T substantially reduces acquisition time while maintaining comparable quantitative and qualitative image quality. This may pave the way for protocol abbreviation especially in a high-throughput clinical workspace.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.15249DOI Listing
September 2021

[Treatment of IBS with Lactobacillus plantarum 299v: Therapeutic success increases with length of treatment - real-life data of a non-interventional study in Germany].

Z Gastroenterol 2021 Feb 8;59(2):125-134. Epub 2021 Feb 8.

Institut für Radiologie, Universitätsmedizin Mannheim, Germany.

Introduction:  The treatment of irritable bowel syndrome (IBS) in clinical practice is frequently challenging. Modulation of the intestinal microbiome as a treatment option is becoming more and more important. The effectiveness of a bacterial strain, 299v (LP299V), was previously investigated in placebo-controlled clinical trials in patients with IBS over 4 weeks. The aims of the present non-interventional study were therefore to investigate tolerability and effectiveness of LP299V under everyday conditions and to gain information on long-term treatment.

Methods:  Data on tolerability and effectiveness of LP299V (1 capsule/day; 1 × 10 CFU) were prospectively collected in 25 centers in 221 patients with IBS. The maximal treatment duration was 12 weeks. The survey was carried out using symptom diaries and medical assessments. Changes in frequency and severity of symptoms were compared to baseline and defined the primary endpoint.

Results:  During the 12-week treatment, a significant and continuous reduction of overall symptom score (p < 0.05) was observed. In addition, a significant reduction of severity (S) and frequency (H) of individual symptoms, such as abdominal pain (S: - 67 %, H: - 51 %), flatulence (S: - 61 %, H: - 63 %), diarrhea (S: - 70 %, H: - 32 %) and constipation (S: - 79 %, H: - 6 %) was observed. Urgency and feeling of incomplete evacuation were significantly decreased (p < 0.001). Additionally, quality of life increased significantly (mental well-being: + 110 %, influence on everyday life: -67 %, p < 0.01). Self-assessment identified that long-term treatment with LP299V was tolerated well by 94 % of patients.

Conclusion:  In real life, LP299V significantly alleviates the global symptoms of IBS in patients. In order to achieve the maximum effect, long-term use of LP299V (as here 12 weeks) appears to be indicated and is well tolerated.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1340-0204DOI Listing
February 2021

Acute pulmonary embolism mimicking COVID - 19 pneumonia.

Int J Infect Dis 2020 07 18;96:475-476. Epub 2020 May 18.

Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, D-68167, Germany.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2020.05.053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233210PMC
July 2020

Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.

Eur Heart J 2015 Nov 6;36(43):3007-16. Epub 2015 Aug 6.

Mannheim Medical Faculty, Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria Synlab Academy, Mannheim, Germany

Aims: High-density lipoproteins (HDLs) are considered as anti-atherogenic. Recent experimental findings suggest that their biological properties can be modified in certain clinical conditions by accumulation of serum amyloid A (SAA). The effect of SAA on the association between HDL-cholesterol (HDL-C) and cardiovascular outcome remains unknown.

Methods And Results: We examined the association of SAA and HDL-C with mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, which included 3310 patients undergoing coronary angiography. To validate our findings, we analysed 1255 participants of the German Diabetes and Dialysis study (4D) and 4027 participants of the Cooperative Health Research in the Region of Augsburg (KORA) S4 study. In LURIC, SAA concentrations predicted all-cause and cardiovascular mortality. In patients with low SAA, higher HDL-C was associated with lower all-cause and cardiovascular mortality. In contrast, in patients with high SAA, higher HDL-C was associated with increased all-cause and cardiovascular mortality, indicating that SAA indeed modifies the beneficial properties of HDL. We complemented these clinical observations by in vitro experiments, in which SAA impaired vascular functions of HDL. We further derived a formula for the simple calculation of the amount of biologically 'effective' HDL-C based on measured HDL-C and SAA from the LURIC study. In 4D and KORA S4 studies, we found that measured HDL-C was not associated with clinical outcomes, whereas calculated 'effective' HDL-C significantly predicted better outcome.

Conclusion: The acute-phase protein SAA modifies the biological effects of HDL-C in several clinical conditions. The concomitant measurement of SAA is a simple, useful, and clinically applicable surrogate for the vascular functionality of HDL.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehv352DOI Listing
November 2015
-->